https://www.selleckchem.com/pr....oducts/Pomalidomide(
The association between the pharmacokinetics and pharmacodynamics of regorafenib, a multiple tyrosine kinase inhibitor, remains unclear. This study assessed the trough plasma concentrations (C ) of regorafenib and its N-oxide (M2) and N-oxide/desmethyl (M5)metabolites, and evaluated the associations among these levels, adverse events, and pharmacokinetic-related genetic polymorphisms in patients with metastatic colorectal cancer. The C levels of regorafenib and its metabolites were assessed in a single-center, prospective,
Like
Comment
Share
